Successful treatment of major pemphigus vulgaris relapse with mycophenolate mofetil and high-potent topical corticosteroid

Nafiseh Esmaili, MD
Cheyda Chams-Davatchi, MD
Maryam Daneshpazhooh, MD
Maryam Ghiasi, MD
Robabe Abedini, MD
Hossein Mortazavi, MD
Iman Roghani, MD

Autoimmune Bollous Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran

Corresponding Author:
Robabe Abedini, MD
Autoimmune Bollous Disease Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

Conflict of interest: none to declare

INTRODUCTION

Pemphigus vulgaris (PV) is a rare autoimmune bullous disorder that is fatal if left untreated. High dose systemic corticosteroids are the basis of therapy. The introduction of adjuvant immunosuppressive agents has improved the disease outcome and reduced the required corticosteroid dose and related toxicity. However, the optimal immunosuppressive agent has not yet been recognized. Mycophenolate Mofetil (MMF) is one of these immunosuppressive drugs with which successful treatment of pemphigus vulgaris has been reported, as an adjuvant or taper-off corticosteroid.

Background: Pemphigus vulgaris (PV) is an autoimmune bullous disorder that is fatal if left untreated. High dose systemic corticosteroids are the basis of therapy. The addition of immunosuppressive agents has improved the disease outcome and reduced the required corticosteroid dose and related toxicity. Mycophenolate mofetil is increasingly used as a steroid-sparing agent in immunotherapy of PV. Herein, we tried to appraise the efficacy of mycophenolate mofetil and topical clobetasol in the control of the major relapses of pemphigus vulgaris.

Method: Seventeen patients with severe relapse of pemphigus vulgaris were included in this study. All patients had complete remission on/off therapy before this period of recurrence. The patients were treated with 2g/day mycophenolate mofetil and 25-35g/day topical clobetasol propionate ointment. All patients were monitored for the side effects of therapy.

Result: The patients were followed for a mean period of 12.7 months. The average length of time from initiating mycophenolate to 50% control (partial remission), which occurred in all patients, was 6±1.17 weeks. Fifteen patients achieved complete remission averagely at week 20.8±7.70. The average duration of follow-up after complete disease control was 8 months (ranging from 2-13.5 months). Three patients were free of lesions for more than 12 months and 10 for more than 6 months. No important mycophenolate mofetil related complication was observed during treatment.

Conclusion: The combination of mycophenolate mofetil and topical corticosteroid can be used to control PV relapses and taper-off corticosteroid.

Keywords: clobetasol propionate, mycophenolate mofetil, pemphigus vulgaris, relapse, treatment

as monotherapy. This study describes our experience of the use of MMF and topical clobetasol propionate in the management of 17 patients with severe relapse of PV without the classic increase in their low dose steroid intake.

PATIENTS AND METHODS

Patients

Seventeen patients with severe relapse of pemphigus vulgaris (PV) were included prospectively in this study. All of the patients had complete remission on/off therapy before this period of recurrence. The patients had not received any additional immunosuppressive therapy during the 3 months preceding the relapse and the total daily dose of oral prednisolone was ≤ 10 mg. Previous treatment regimens that caused remission before the current relapse are presented in Table 1.

PV had been diagnosed on the basis of (I) clinical criteria: flaccid skin and/or mucosal blisters; (II) histological criteria: suprabasal acantholysis, leading to clefts and subsequent blistering, and eosinophilic spongiosis and (III) direct immunofluorescence: deposition of IgG, complement 3 (C3) or both on keratinocyte membranes. All patients had contraindication(s) to high dose corticosteroids because of severe associated medical conditions (Table 1) and completed informed consent forms before the initiation of therapy. Severe relapse was defined as the occurrence of at least five cutaneous or mucosal lesions per day during the period when minimal therapy was given.

Treatment

The patients were treated with 2g/day

Table 1. Summary of demographic characterization, clinical presentation at the baseline and follow-up period

<table>
<thead>
<tr>
<th>Number</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Type</th>
<th>Disease period (years)</th>
<th>Last relapse (years ago)</th>
<th>Prednisolone dose (mg/day)</th>
<th>Clobetasol (tube/day)</th>
<th>Contraindication for high dose prednisolone</th>
<th>Number of lesions</th>
<th>Pemphigus severity score</th>
<th>Time to complete remission (weeks)</th>
<th>Follow-up period (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>52</td>
<td>MC</td>
<td>10</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>Osteoporosis</td>
<td>14</td>
<td>4</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>46</td>
<td>MC</td>
<td>4</td>
<td>-</td>
<td>10</td>
<td>3.5</td>
<td>cataract, Hypertension, Nephrolithiasis</td>
<td>20</td>
<td>7</td>
<td>28</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>57</td>
<td>MC</td>
<td>1</td>
<td>-</td>
<td>0</td>
<td>2.5</td>
<td>Diabetes Mellitus</td>
<td>20</td>
<td>7</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>37</td>
<td>MC</td>
<td>1</td>
<td>-</td>
<td>10</td>
<td>3</td>
<td>Hypertension</td>
<td>38</td>
<td>7</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>30</td>
<td>MC</td>
<td>8</td>
<td>3</td>
<td>0</td>
<td>3.5</td>
<td>Necrosis of the femoral head</td>
<td>42</td>
<td>11</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>60</td>
<td>MC</td>
<td>6</td>
<td>3</td>
<td>10</td>
<td>3</td>
<td>Diabetes Mellitus, Congestive heart failure</td>
<td>45</td>
<td>10</td>
<td>24</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>40</td>
<td>C</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>8.75</td>
<td>Cataract</td>
<td>42</td>
<td>8</td>
<td>24</td>
<td>14</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>70</td>
<td>MC</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>6.25</td>
<td>Cataract, Glaucoma</td>
<td>24</td>
<td>5</td>
<td>16</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>76</td>
<td>MC</td>
<td>5</td>
<td>1</td>
<td>10</td>
<td>2.5</td>
<td>Hypertension, Cataract, Glaucoma</td>
<td>34</td>
<td>8</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>66</td>
<td>MC</td>
<td>12</td>
<td>1</td>
<td>2.5</td>
<td>3</td>
<td>Hyper tension, Cataract, Osteoporosis, Diabetes Mellitus</td>
<td>46</td>
<td>12</td>
<td>40</td>
<td>14</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>56</td>
<td>MC</td>
<td>6</td>
<td>3</td>
<td>7.5</td>
<td>2.5</td>
<td>Diabetes Mellitus</td>
<td>23</td>
<td>7</td>
<td>16</td>
<td>-</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>53</td>
<td>MC</td>
<td>3</td>
<td>-</td>
<td>5</td>
<td>3</td>
<td>Necrosis of the femoral head</td>
<td>17</td>
<td>7</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>43</td>
<td>M</td>
<td>6</td>
<td>1</td>
<td>8.25</td>
<td>3</td>
<td>Hypertension, Diabetes M38ellitus, Central retinal artery obstruction</td>
<td>10</td>
<td>4</td>
<td>16</td>
<td>14</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>33</td>
<td>MC</td>
<td>2</td>
<td>-</td>
<td>10</td>
<td>2.5</td>
<td>Peptic ulcer disease</td>
<td>12</td>
<td>5</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>38</td>
<td>MC</td>
<td>2</td>
<td>-</td>
<td>10</td>
<td>2.5</td>
<td>Glaucoma</td>
<td>38</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>52</td>
<td>MC</td>
<td>6</td>
<td>1</td>
<td>10</td>
<td>3</td>
<td>Diabetes Mellitus, Osteoporosis</td>
<td>16</td>
<td>6</td>
<td>24</td>
<td>8</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>45</td>
<td>C</td>
<td>15</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>Osteoporosis</td>
<td>11</td>
<td>4</td>
<td>12</td>
<td>6</td>
</tr>
</tbody>
</table>

C, cutaneous; M, mucosal; MC, mucocutaneous
mycophenolate mofetil (MMF: 500 mg four times per day). The clobetasol propionate ointment was initially used at the dose of 25-35 g/day. The dose was tapered 5g/day each two weeks and was discontinued after about 10-12 weeks. Oral prednisolone was maintained at the previous dose (≤ 10 mg/day) until the disease was controlled. Patients who did not receive oral corticosteroids at the time of recurrence were treated with MMF alone.

**Efficacy and safety**

Clinical disease severity was assessed on the first visit according to a four-point scoring system as shown in Table 2. For every patient, the scores were determined for each skin area/mucosal surface and summed at baseline and then at weekly intervals thereafter. At each visit, the patients were inquired about the adverse events and monitored by routine biochemical and hematological tests with a special focus on leukocyte counts. The patients were followed for at least 6 months.

Complete remission was defined as the epithelialization of all skin and mucosal lesions, partial remission as the epithelialization of more than 50% of the lesions but not of all lesions, and relapse as the occurrence of new cutaneous or mucosal erosions.

**RESULTS**

Seventeen patients (13 females, 4 males) entered the study. The mean age of the patients was 50.18 years (ranging from 30-76 years). Fourteen patients had mucocutaneous involvement; one and two patients had only mucosal and cutaneous involvement, respectively. All included patient had severe PV relapses when they entered the study. Before the PV relapse, all patients were in complete remission on low dose/off prednisolone therapy. The patients were receiving a mean prednisolone dosage of 6.3 mg/day (ranging from 0-10 mg) and all had at least one contraindication for high dose steroid therapy (Table 1). Clinically, they averagely had 27 (ranging from 10-46) lesions at the beginning of the study and mean pemphigus severity score (PSS) was 7.23 (ranging from 4-12).

The patients were followed for a mean period of 12.7 months (6-17 months). The average length of time from initiating MMF to 50% control (partial remission), which occurred in all patients, was 6±1.17 weeks.

Improvement in PSS continued for all patients until week 16, after which two patients developed severe relapses (at weeks 16 and 32, respectively) on MMF and were therefore excluded from the study. Thus, fifteen patients achieved complete remission averagely at week 20.8±7.70. Two other patients were excluded at weeks 24 and 32 because of non-authorized discontinuation of MMF. The average duration of follow-up after complete disease control was 8 months (ranging from 2-13.5 months). Three patients were free of lesions for more than 12 months and 10 for more than 6 months (Figure 1), indicating the decline in

**Table 2. Pemphigus severity score**

<table>
<thead>
<tr>
<th>Areas of the body</th>
<th>Skin lesions</th>
<th>Mucosal lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Score</td>
<td>Involved mucosa</td>
</tr>
<tr>
<td>Face</td>
<td>Nil: 0</td>
<td>Oral</td>
</tr>
<tr>
<td>Scalp</td>
<td>Mild:1-2</td>
<td>Nasal</td>
</tr>
<tr>
<td>Nose skin</td>
<td>Moderate:3-5</td>
<td>Larynx</td>
</tr>
<tr>
<td>Breast</td>
<td>Severe:6</td>
<td>Conjunctiva</td>
</tr>
<tr>
<td>Axilla</td>
<td></td>
<td>Genital</td>
</tr>
<tr>
<td>Groin</td>
<td></td>
<td>Urethra</td>
</tr>
<tr>
<td>Thorax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdomen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limbs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Changes of mean Pemphigus severity score (black) and lesion numbers (gray) during treatment period.
PSS during treatment. No important MMF related complication was reported during treatment.

**DISCUSSION**

**Pemphigus vulgaris** still has a high rate of therapy related morbidity after long periods of high-dose steroid therapy. Novel immunosuppressive agents have been introduced to spare steroids and reduce such complications. MMF is an immunosuppressive drug that was primarily applied in kidney and other organ allografts to prevent rejections. It is a prodrug of mycophenolic acid (MPA), which inhibits synthesis of guanosine nucleotides.

Because T and B lymphocytes are highly dependent on the de novo pathway for the production of guanosine nucleotides, MPA selectively inhibits their proliferation and antibody production. MPA also inhibits glycosylation and the expression of some adhesion molecules in lymphocytes and monocytes. In treated patients, the percentages of CD38+ B cells and activated T/NK cells were reduced during therapy.

In doses of up to 2 g/d, MMF is usually well tolerated without significant myelosuppression, hepatotoxicity, or nephrotoxicity. Because of its lower toxicity profile and selective mechanism of action, MMF represents a good choice for immunotherapy. Several reports have showed successful treatment of PV with MMF in combination with high-dose prednisolone, or as monotherapy. We also previously reported that the combination of prednisolone and MMF could be used successfully and safely in the treatment of non-generalized forms of PV.

These studies mainly focus on the treatment of active PV or PV that is refractory to other therapies. In fact, few studies have exclusively evaluated its efficacy in the treatment of PV relapses. Mimouni et al, published a study of 31 PV patients who had relapses during prednisolone tapering or had clinically significant adverse effects from previous drug therapy. They found that remission was achieved with MMF in 22 (71%) of the patients. The median time to achieve complete remission was 9 months (range, 1-13 months).

We evaluated the effectiveness of MMF and topical clobetasol in the control of major relapses of pemphigus vulgaris. The PV relapses were controlled in 76% of our patients without any increase in the prednisolone dose. Complete remission was achieved earlier (about 5 months) in our study as compared to the study conducted by Mimouni et al.

We started MMF at the dose of 2g/day and did not observe any significant side effects. Our previous study showed an increased incidence of bacterial and viral infections in PV patients treated with the combination of MMF (2g/day) and prednisolone (2mg/kg). Thus, the steroid sparing effect of MMF (as shown in the current study) is significant in terms of reducing steroid-related toxicity.

Although high dose topical clobetasol has systemic effects similar to oral prednisolone, our experience showed that the side effects of this type of therapy were insignificant. Moreover, we successfully tapered it off in 10-12 weeks.

In our series, clinical severity was ameliorated with reducing PSS (Figure 1) after introduction of MMF and topical clobetasol propionate. MMF was well tolerated and we could discontinue all the medications in 3 patients after one year. Our study showed that combination of MMF and topical clobetasol not only could control severe PV relapses but also induced long term remission in some patients.

According to our experiences, MMF may be highly effective for patients with even severe PV relapses who cannot continue high-dose systemic steroids. This therapy offers the advantage of fewer adverse effects in comparison with immunosuppressive/systemic steroid combination therapy and, therefore, is very well tolerated by patients. In a recent randomized clinical trial, patients with active PV responded to MMF quickly, and were in remission for a longer time before relapse.

In conclusion, our study showed that the combination of MMF and topical corticosteroid could be used to control PV relapses and taper-off corticosteroid just to MMF when the patients have contraindications to high dose corticosteroids.

**REFERENCES**

3. Lever WF, Schaumburg-Lever G. Treatment of pemphigus
Treatment of pemphigus vulgaris relapse with Mycophenolate Mofetil